OLTEN, Switzerland, Jan. 18, 2013 /CNW/ - Reha Technology AG announced
today the closing of financing by HBM BioCapital II LP; a private
equity partnership advised by HBM Partners AG, Switzerland.
Reha Technology AG, a Swiss company, designs, manufactures and globally
distributes advanced robotic-assisted systems for neurorehabilitation.
The development for the patented G-EO System™ which is the world's
first and only gait rehabilitation device with the ability to simulate
stair climbing up and down, started in 2007 in Bolzano, Italy. The
company began operations in Switzerland in 2012. Since then, a
worldwide distributor network and operations in the United States have
been established. The expansion of the global network and the launch of
additional products are the primary goals for 2013.
In connection with the financing, HBM BioCapital II acquired a
significant minority stake in Reha Technology AG. The capital will be
used to further expand Reha Technology's business on a worldwide basis.
HBM is a major European healthcare investor with assets of around $800
million under management. HBM supports pharma, medical technology and
diagnostics companies in their worldwide business expansion.
René Trost, CEO of Reha Technology AG, comments: "We are proud that we
were able to attract a major healthcare investor as a new shareholder
for Reha Technology. With the support of HBM, we will be able to
substantially expand and grow our business of selling the most advanced
rehabilitation robotic systems to customers around the world."
About Reha Technology AG
Reha Technology AG improves the quality of life for all those who have
been injured or disabled by illness or accident. To achieve this goal,
the company uses research and development of new technologies in
robotics focusing on robotic assisted rehabilitation and makes the
newest and most effective technologies available for medical
rehabilitation devices. FOR A BETTER LIFE.
About HBM Partners
HBM Partners is among the global leaders in healthcare-focused investing
with approximately $800 million under management. HBM focuses on
development-stage, growth and buy-out financings of private companies
as well as investments in public companies. HBM Partners advises HBM
Healthcare Investments AG, HBM BioCapital I & II and further
specialized private-equity and public-equity funds. HBM has been an
active contributor to value creation in portfolio companies, generating
over 40 trade sales and IPOs since inception. For more information
SOURCE: REHA Technology AG
For further information:
Reha Technology AG
René Trost, CEO